Sign in

TLSA on Nasdaq

Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd is a pharmaceutical preparations company based in Hamilton, Bermuda.2 Its shares trade on Nasdaq under the symbol TLSA.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerTLSA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersHamilton, Bermuda2
  • Incorporated inBermuda3
  • Business address3Rd Floor, 11-12 St. James'S Square, London, England, X0 Sw1Y 4Lb3
  • Filer categoryNon-accelerated filer3
  • Legal formExempted Companies Limited by Shares2
  • LEI984500769407C5E46F422
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressRichmond House, 12 Par-la-Ville Road, HM 08 Hamilton, Bermuda2
  • Registered withRegistrar of Companies (Ministry of Economic Development), 554082

See how the biggest companies compare on our leaderboards

Tiziana Life Sciences plc), Tiziana Therapeutics Inc., Tiziana Pharma Limited and Longevia Genomics S.r.l.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$15.8M in 2024+60% since 2018
-$30.0M-$20.0M-$10.0M02018: -$9.9M-$9.9M20182019: -$9.9M-$9.9M2019+1%2020: -$28.0M-$28.0M2020+182%2021: -$27.4M-$27.4M2021−2%2022: -$14.6M-$14.6M2022−47%2023: -$18.0M-$18.0M2023+23%2024: -$15.8M-$15.8M2024−12%
Net income56789-$11.9M in 2024+50% since 2018
-$30.0M-$20.0M-$10.0M02018: -$7.9M-$7.9M20182019: -$9.3M-$9.3M2019+18%2020: -$26.1M-$26.1M2020+180%2021: -$23.4M-$23.4M2021−10%2022: -$15.4M-$15.4M2022−34%2023: -$17.7M-$17.7M2023+15%2024: -$11.9M-$11.9M2024−33%

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Research and Development-$10.3M-$5.2M-$8.1M
Operating expenses-$10.9M-$10.6M-$9.9M
Total operating expenses-$21.1M-$15.8M-$18.0M
Loss from operations-$21.1M-$15.8M-$18.0M
Finance income$1.0K$814.0K$1.1M
FV Gain/(Loss) on Investment$2.3M-$1.8M-$402.0K
Gain/on sale of Investment$367.0K
Total other income/(expense)$2.7M-$952.0K$742.0K
Loss from operations before income taxes-$18.4M-$16.7M-$17.2M
Income tax credit/(expense)$4.9M-$449.0K
Loss for the year-$18.4M-$11.9M-$17.7M
Gain/(Loss) on currency translation-$88.0K-$72.0K$1.5M
Comprehensive loss-$18.5M-$11.9M-$16.2M
Basic loss per share attributable to common shareholders (in Dollars per share)-$0.16-$0.11-$0.17
Diluted loss per share attributable to common shareholders (in Dollars per share)-$0.16-$0.11-$0.17

Compare Tiziana Life Sciences Ltd with another company

Corporate structure

Tiziana Life Sciences Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Tiziana Life Sciences Ltd

  • Jorey Chernett Filed SCHEDULE 13G/A on Tiziana Life Sciences Ltd, latest Dec 10, 2025 (3 filings since Jun 12, 2025)
  • Laura Natalia Monica Fonda Filed SCHEDULE 13G on Tiziana Life Sciences Ltd, latest Oct 28, 2025 (2 filings since May 4, 2022)
  • Gabriele M. Cerrone Filed SC 13D on Tiziana Life Sciences Ltd, latest Jan 4, 2022
  • Tiziana Life Sciences Ltd Hamilton, Bermuda

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Tiziana Life Sciences Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$16.0K9 Dec 31, 2024$10.0K9 Dec 31, 2023+60.0%
Operating-lease assets (leased space)$171.0K9 Dec 31, 2024$283.0K9 Dec 31, 2023−39.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.7M9 Dec 31, 2024$1.2M9 Dec 31, 2023+214.8%

Leadership

Who has led Tiziana Life Sciences Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ivor Elrifi2026–now
Board members and other officers (1)

Former names

  • Tiziana Life Sciences plcNov 30, 2017 to Oct 21, 20213

Timeline

  1. Jul 23, 2026New chief executive Ivor Elrifi becomes CEO12
  2. Mar 20, 2020Founded Tiziana Life Sciences Ltd is founded2

Calendar

Drug trials and FDA: coming up

  1. Apr 1, 2027Phase 2 trial readout expected Phase 2 trial of Foralumab Nasal in Multiple System Atrophy: primary completion expected Apr 1, 2027 (ClinicalTrials.gov NCT06868628).13
  2. Jul 2027Phase 2 trial readout expected Phase 2 trial of Foralumab Nasal in ALS (Amyotrophic Lateral Sclerosis): primary completion expected Jul 2027 (ClinicalTrials.gov NCT07688239).14

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

245 filings to the SEC since October 2021: 7 annual reports, 1 major events, 10 insider forms, 6 large holders, 221 other. The latest 20:

  1. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Sep 29, 20264 EDGAR
  3. Sep 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 7, 20264/A EDGAR
  8. Aug 7, 20264/A EDGAR
  9. Aug 6, 20264 EDGAR
  10. Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Aug 5, 20264 EDGAR
  12. Aug 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Jul 23, 20263 EDGAR
  15. Jul 23, 20264 EDGAR
  16. Jul 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Jun 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jun 17, 20264 EDGAR
  19. Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. May 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 245 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 5, 2026Elrifi IvorChief Executive OfficerBuy237,616$1.00$237.6KForm 4
Aug 4, 2026Elrifi IvorChief Executive OfficerBuy83,807$0.97$81.3KForm 4
Aug 3, 2026Elrifi IvorChief Executive OfficerBuy667,000$1.00$667.0KForm 4
Jul 21, 2026CERRONE GABRIELE MDirectorBuy42,357$0.99$41.9KForm 4
Jun 12, 2026CERRONE GABRIELE MDirectorBuy15,000$1.11$16.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Jorey ChernettSCHEDULE 13G/A, 3 filings Jun 12, 2025 to Dec 10, 202515
  • Laura Natalia Monica FondaSCHEDULE 13G, 2 filings May 4, 2022 to Oct 28, 202516
  • Gabriele M. CerroneSC 13D, 1 filing Jan 4, 202217

SEC filer profile

How Tiziana Life Sciences Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTiziana Life Sciences Ltd1
  • CIK0001723069
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inBermuda4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3Rd Floor, 11-12 St. James'S Square, London, England, X0 SW1Y 4LB1
  • Phone0044(0) 207-495-23791
  • Shares outstanding120,507,401 shares as of Dec 31, 20254
  • AuditorPKF Littlejohn LLP, London, England PCAOB ID 2814; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceNov 30, 20171
  • Filings486 in all: 6-K (346), CORRESP (21), UPLOAD (12), 424B5 (10), 20-F (8), DRS/A (7), F-1/A (7), DRS (6)1
    All 38 form types

    EFFECT (6), FWP (6), NT 20-F (6), 4 (5), DRSLTR (4), 3 (3), F-3 (3), F-3/A (3), F-6 POS (3), SC 13G (3), 20-F/A (2), 4/A (2), F-1 (2), POS AM (2), SC 13G/A (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 25-NSE (1), 424B4 (1), 6-K/A (1), 8-A12B (1), 8-K12B (1), AW (1), CERT (1), F-6 (1), F-6/A (1), F-6EF (1), RW (1), S-8 (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) May 1, 2026

Securities registered for trading

ClassSymbolExchange
Common SharesTLSANASDAQ

From the cover page of the 20-F filed May 1, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17